AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 31 min read$TVTX

Travere: Q3 Earnings Snapshot

Travere Therapeutics (TVTX) reported a Q3 loss of $52.3M, or 55 cents per share, missing analyst estimates of a 25 cents loss per share. Revenue was $224.6M, exceeding forecasts of $192.5M. The drug developer's earnings fell short of expectations.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 4:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 4:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Travere: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TVTXBearishMed
01

Why it matters

The earnings miss on loss per share may trigger a sell‑off, but the revenue beat suggests underlying demand.

02

Market read

First‑report Q3 earnings for a micro‑cap biotech; relevant for traders monitoring earnings surprises.

03

What to watch

Potential pipeline milestones not disclosed could offset earnings disappointment.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

Travere Therapeutics (TVTX) is a specialty biopharma focused on rare kidney diseases.

Company-level read

Ticker impact

$TVTXBearishHigh confidence
Context

Travere Therapeutics reported Q3 results with a loss of $52.3M, 55c per share versus expectations of a 25c loss, and revenue of $224.6M beating forecasts.

Expected impact

likely pressure as the market prices in the larger-than-expected loss

Evidence & confidence

The loss per share was more than double analyst expectations, a clear downside catalyst.

Market effects

Sector

Biotech earnings miss may weigh on small‑cap pharma sentiment.

Regional

Limited to U.S. biotech investors.

Global

Low; impact confined to the company's shareholders.

Counterpoint

What could challenge this read

Revenue beat could support a short‑term bounce if investors focus on top‑line growth.

Key entities

  • company
    Travere Therapeutics

    Issuer of the earnings report.

Read at source← All news

StoryTravere Therapeutics reports Q3 2026 loss and revenue beat amid high R&D spend

Also covered by

3 outlets

Related articles

NOV 3
$TVTXMedAI 8/10

Why is Travere Therapeutics stock sliding today?

Travere Therapeutics (TVTX) shares fell 4.3% in pre-market trading after reporting Q3 2026 results. The company missed earnings estimates due to a $113.1M R&D expense, despite revenue beating expectations. Leerink Partners cut its price target to $67 from $78. CEO Eric Dube sold shares in mid-October. FILSPARI sales grew 120% YoY, but Q4 inventory normalization may impact revenue.

investing.com6 min
NOV 3
$TVTXMed

Travere (TVTX) Q3 2026 Earnings Call Transcript

Travere (TVTX) reported Q3 2026 earnings, highlighting strong performance of its drug Filspari, with quarterly net product sales surpassing $200 million. The company expects to achieve or exceed $3 billion in annual Filspari sales by 2033, driven by growing patient demand and a strengthened patent portfolio. Travere also discussed progress in its pipeline, including Pegtibatinase for classical HCU and Civorebrutinib for immune-mediated kidney diseases.

finance.yahoo.com3 min
NOV 3
$TVTXMed

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

Travere Therapeutics (TVTX) reported Q3 earnings, with FILSPARI sales at $8M. The company expects Q4 sales to be reduced by a similar amount due to inventory adjustments. TVTX sees opportunities for FILSPARI in the evolving IgAN market and highlighted positive clinical data. Expenses totaled $168.7M, including $113.1M in R&D. CEO Eric Dube will step down in December. TVTX reiterated its $3B sales target for FILSPARI by 2033.

finance.yahoo.com3 min